23 April 2021
Probiotic strains approved in India
Blis Technologies announces the Food Safety and Standards Authority of India (FSSAI) has granted approval of both BLIS M18™ and BLIS K12™ probiotic strains for use in health supplements.
Brian Watson, CEO of Blis Technologies, said “The COVID pandemic has caused delays in the normal approval timelines for this approval in India but we are delighted to have finally reached this milestone and look forward to continuing commercialisation plans with our agent for the India market.”
Blis Technologies have an existing relationship with RNA Nutrition who have supported this approval process and will act as our agent for the commercialisation of BLIS Ingredients™ in India. RNA Nutrition is an established selling agent for science based novel ingredients for human and animal health in India with a strong customer base.
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.
Website: www.unconditionalskin.com
Instagram: @unconditionalskin #BLISQ24 #USC
Facebook: @unconditionalskin
The S&P/NZX 50 Index closed at 23,307.27, down 224.45 points or 1.79%.
Mercury reports first ever net loss after tax.
The company is seeking a reset after a glut of honey and bad news.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details